Cargando…

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib

A subset of patients with differentiated thyroid carcinoma develop radioiodine refractory (RAIR) incurable disease, which typically has a poor prognosis. The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukrithan, Vineeth, Kim, Lisa, Sipos, Jennifer A., Goyal, Ashima, Zhou, Ye, Addison, Daniel, Shah, Manisha, Konda, Bhavana, Vallakati, Ajay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629999/ https://www.ncbi.nlm.nih.gov/pubmed/37941892 http://dx.doi.org/10.1155/2023/8841696

Ejemplares similares

Kinase inhibitors in thyroid cancers
por: Sukrithan, Vineeth, et al.
Publicado: (2023)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
por: Kim, Lisa, et al.
Publicado: (2021)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib
por: Saito, Kei, et al.
Publicado: (2020)

Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer
por: Molinaro, Eleonora, et al.
Publicado: (2019)

Pancreatic Cancer Heralded by Worsening Glycemic Control: A Report of Two Cases
por: Desai, Dimpi, et al.
Publicado: (2017)

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
por: Tohyama, Osamu, et al.
Publicado: (2014)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
por: Furuto, Yoshitaka, et al.
Publicado: (2018)

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
por: Dierks, Christine, et al.
Publicado: (2021)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Brose, Marcia S, et al.
Publicado: (2021)

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib
por: Kimura-Tsuchiya, Reiko, et al.
Publicado: (2018)

Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib
por: Jin, Meihua, et al.
Publicado: (2023)

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum
por: Yanagihara, Toyoshi, et al.
Publicado: (2021)

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
por: Decraecker, Marie, et al.
Publicado: (2021)

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma
por: Peng, Chunying, et al.
Publicado: (2023)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
por: Wiegering, Armin, et al.
Publicado: (2014)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Systemic mastocytosis presenting as cardiac tamponade with CD25(+) pericardial mast cells
por: Sukrithan, Vineeth K., et al.
Publicado: (2016)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
por: Costa, Ricardo, et al.
Publicado: (2016)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020)

Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
por: Toda, Soji, et al.
Publicado: (2021)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rgmc3hhfknd38d3h3910je537o